Foamix Reports Fiscal Year 2017 Financial Results and Provides Corporate Update

Pharmaceutical Investing

Foamix Pharmaceuticals (NASDAQ:FOMX) a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today financial results for the fiscal year ended December 31, 2017. As quoted in the press release: Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, …

Foamix Pharmaceuticals (NASDAQ:FOMX) a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today financial results for the fiscal year ended December 31, 2017.

As quoted in the press release:

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our leading clinical stage product candidates are FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne and FMX103, our novel minocycline foam for the treatment of rosacea. We continue to pursue research & development of our proprietary, innovative foam technologies for the treatment of various skin conditions. We currently have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

Click here to read the full press release.

The Conversation (0)
Ă—